Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus acarbose for glycemic fluctuation in type 2 diabetes using CGMS
ChiCTR1800017878Phase 4Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin and acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: Mean amplitude of glycemic excursions, Coefficient of variation of blood glucose and 1 more. Started Aug 2018; status: recruiting.
02
Drugs
dapagliflozinacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1800017878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017878.